Literature DB >> 22645358

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.

Nancie M Archin1, Naveen K Vaidya, Joann D Kuruc, Abigail L Liberty, Ann Wiegand, Mary F Kearney, Myron S Cohen, John M Coffin, Ronald J Bosch, Cynthia L Gay, Joseph J Eron, David M Margolis, Alan S Perelson.   

Abstract

HIV type 1 (HIV-1) persists within resting CD4(+) T cells despite antiretroviral therapy (ART). To better understand the kinetics by which resting cell infection (RCI) is established, we developed a mathematical model that accurately predicts (r = 0.65, P = 2.5 × 10(-4)) the initial frequency of RCI measured about 1 year postinfection, based on the time of ART initiation and the dynamic changes in viremia and CD4(+) T cells. In the largest cohort of patients treated during acute seronegative HIV infection (AHI) in whom RCI has been stringently quantified, we found that early ART reduced the generation of latently infected cells. Although RCI declined after the first year of ART in most acutely infected patients, there was a striking absence of decline when initial RCI frequency was less than 0.5 per million. Notably, low-level viremia was observed more frequently as RCI increased. Together these observations suggest that (i) the degree of RCI is directly related to the availability of CD4(+) T cells susceptible to HIV, whether viremia is controlled by the immune response and/or ART; and (ii) that two pools of infected resting CD4(+) T cells exist, namely, less stable cells, observable in patients in whom viremia is not well controlled in early infection, and extremely stable cells that are established despite early ART. These findings reinforce and extend the concept that new approaches will be needed to eradicate HIV infection, and, in particular, highlight the need to target the extremely small but universal, long-lived latent reservoir.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22645358      PMCID: PMC3386138          DOI: 10.1073/pnas.1120248109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Maximum likelihood inference for left-censored HIV RNA data.

Authors:  H S Lynn
Journal:  Stat Med       Date:  2001-01-15       Impact factor: 2.373

Review 2.  The challenge of viral reservoirs in HIV-1 infection.

Authors:  Joel N Blankson; Deborah Persaud; Robert F Siliciano
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

4.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

5.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

6.  Determining the relative efficacy of highly active antiretroviral therapy.

Authors:  Michael Louie; Christine Hogan; Michele Di Mascio; Arlene Hurley; Viviana Simon; James Rooney; Nancy Ruiz; Scott Brun; Eugene Sun; Alan S Perelson; David D Ho; Martin Markowitz
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

7.  High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.

Authors:  S J Clark; M S Saag; W D Decker; S Campbell-Hill; J L Roberson; P J Veldkamp; J C Kappes; B H Hahn; G M Shaw
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

8.  Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2003-09-01       Impact factor: 3.731

9.  New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Authors:  Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

10.  Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy.

Authors:  Cynthia Gay; Oliver Dibben; Jeffrey A Anderson; Andrea Stacey; Ashley J Mayo; Philip J Norris; JoAnn D Kuruc; Jesus F Salazar-Gonzalez; Hui Li; Brandon F Keele; Charles Hicks; David Margolis; Guido Ferrari; Barton Haynes; Ronald Swanstrom; George M Shaw; Beatrice H Hahn; Joseph J Eron; Persephone Borrow; Myron S Cohen
Journal:  PLoS One       Date:  2011-05-10       Impact factor: 3.240

View more
  128 in total

1.  CRISPR-mediated Activation of Latent HIV-1 Expression.

Authors:  Prajit Limsirichai; Thomas Gaj; David V Schaffer
Journal:  Mol Ther       Date:  2015-11-26       Impact factor: 11.454

Review 2.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

3.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Authors:  Amanda M Crooks; Rosalie Bateson; Anna B Cope; Noelle P Dahl; Morgan K Griggs; JoAnn D Kuruc; Cynthia L Gay; Joseph J Eron; David M Margolis; Ronald J Bosch; Nancie M Archin
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

4.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

5.  Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

Authors:  Cynthia L Gay; Mark A DeBenedette; Irina Y Tcherepanova; Alicia Gamble; Whitney E Lewis; Anna B Cope; JoAnn D Kuruc; Kara S McGee; Mary F Kearney; John M Coffin; Nancie M Archin; Charles B Hicks; Joseph J Eron; Charles A Nicolette; David M Margolis
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-21       Impact factor: 2.205

6.  A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness.

Authors:  K E Yoder
Journal:  Acta Virol       Date:  2019       Impact factor: 1.162

7.  Early treatment and HIV-1 reservoirs: a stitch in time?

Authors:  Timothy J Henrich; Rajesh T Gandhi
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

8.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

9.  Probabilistic control of HIV latency and transactivation by the Tat gene circuit.

Authors:  Youfang Cao; Xue Lei; Ruy M Ribeiro; Alan S Perelson; Jie Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

10.  Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.

Authors:  Guochun Jiang; Erica A Mendes; Philipp Kaiser; Sumathi Sankaran-Walters; Yuyang Tang; Mariana G Weber; Greg P Melcher; George R Thompson; Amilcar Tanuri; Luiz F Pianowski; Joseph K Wong; Satya Dandekar
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.